98
Participants
Start Date
May 14, 2025
Primary Completion Date
June 1, 2027
Study Completion Date
April 14, 2028
Ruxolitinib
Ruxolitinib twice daily for 56 days followed by a short taper Given orally
Methylprednisolone
Starting dose 2 mg/kg/d for at least three days, then taper Given IV or orally
RECRUITING
Icahn School of Medicine at Mount Sinai, New York
NOT_YET_RECRUITING
Winship Cancer Institute, Emory University, Atlanta
NOT_YET_RECRUITING
Moffitt Cancer Center, Tampa
NOT_YET_RECRUITING
Ohio State University, Columbus
NOT_YET_RECRUITING
Mayo Clinic, Rochester
NOT_YET_RECRUITING
Washington University, St Louis
NOT_YET_RECRUITING
MD Anderson Cancer Center, Houston
NOT_YET_RECRUITING
City of Hope Comprehensive Cancer Center, Duarte
NOT_YET_RECRUITING
Fred Hutchinson Cancer Research Center, Seattle
NOT_YET_RECRUITING
Massachusetts General Hospital, Boston
NOT_YET_RECRUITING
Dana Farber Cancer Institute, Boston
Collaborators (1)
Incyte Corporation
INDUSTRY
National Cancer Institute (NCI)
NIH
John Levine
OTHER